presents
Overview
Our accelerator programme is designed to propel early-stage Biotech startups from concept to preclinical trial readiness, equipping our candidates with the essential knowledge, skills, and networks needed to transition into an investor-ready status. Retincubate kicks off with an intensive three-month course followed by six months of hands-on support and development from our expert team. This all culminates
in an exclusive opportunity to pitch to a prestigious audience at Retinnovate, a premier conference that will together innovators, industry leaders and regulators from both sides of the Atlantic.
Throughout the program, you’ll benefit from a comprehensive curriculum, expert mentorship and access to a wealth of valuable resources. By the end of the course, you will have fine-tuned your pitch and gained the knowledge and confidence to tackle investor questions head-on. Join us on this transformative journey to accelerate the future of healthcare innovation.
Throughout the program, participants can expect to:
-
Develop a comprehensive understanding of the investor landscape and fundraising process within the retinal disease space.
-
Refine their business strategy and value proposition to effectively communicate their vision to investors.
-
Build a network of industry experts, investors, and fellow entrepreneurs to support their growth journey.
-
Receive personalised mentorship and feedback from experienced professionals to address specific challenges and opportunities.
-
Gain exposure to potential investors through pitching opportunities.
-
Access resources and support to navigate regulatory, clinical, and commercialisation hurdles associated with bringing retinal disease therapies to market. By the end of the program, participating companies will be well-positioned to attract investment, accelerate their growth trajectory, and ultimately make a meaningful impact in the field of retinal disease treatment.
Key Dates
-
Deadline to apply: 1st March 2025
-
First session: 4th June 2025
What we offer
-
Access to a new network of similar stage innovators.
-
Introductions to leaders at various points in the idea to clinic pipeline.
-
Dedicated mentorship from one of our program partners between the
-
Collaboration links with leading research institutions
Our program is designed to empower early-stage retinal disease companies with the essential knowledge, skills, and networks needed to transition into an 'investor-ready' status. Through a rigorous curriculum and tailored mentorship, we aim to equip participants with the tools and expertise necessary to navigate the complex landscape of fundraising and secure investment for their ventures.
Selection criteria for participating companies are based on some different factors, including the novelty and potential impact of their technology, the strength of their founding team, and their readiness to engage with investors. We are seeking companies with innovative solutions to address unmet needs in retinal disease treatment. From there, our accelerator program will help you to develop a clear vision for scalability and market potential.’